Advertisement

Retroperitoneal Angiosarcoma

  • Hai Liu
  • Chengli Miao
Chapter

Abstract

Angiosarcoma is a malignant tumor originated in the vascular or lymphatic endothelium. As described in the literature under various names, angiosarcomas were previously called vascular endothelial tumor, ductal sarcoma, angiosarcoma, malignant hemangioendothelioma, and lymphatic sarcoma. It is now known as angiosarcoma, including vascular endothelial derived hemangiosarcoma and lymphangiosarcoma. Hemangiosarcoma cannot be differentiated from lymphangiosarcoma due to lack of reliable morphologic parameters and immunohistochemical features, so they are collectively referred to as angiosarcoma. Angiosarcoma is a rare tumor, commonly seen in skin and soft tissue, accounting for approximately 1–2% of soft tissue sarcoma. Retroperitoneal angiosarcoma is extremely rare as reported in the literature. In this chapter, etiological causes, histopathological features, immunohistochemical markers, clinical manifestation, treatment strategies, therapeutic efficacy, and prognostic factors of angiosarcoma will be briefly described.

References

  1. Al-Abbadi MA, Almasri NM, Al-Quran S. Cytokeratin and epithelial membrane antigen expression in angiosarcomas: an immunohistochemical study of 33 cases. Arch Pathol Lab Med. 2007;131(2):288–92.PubMedPubMedCentralGoogle Scholar
  2. Asano Y, Makino T, Furuichi M. Effective treatment of angiosarcoma on the nose by combination treatment with electron beam irradiation, recombinant interleukin-2 and docetaxel. Clin Exp Dermatol. 2009;34(7):e227–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Colombo C, Randall RL, Andtbacka RH, Gronchi A. Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. Expert Rev Anticancer Ther. 2012;12(8):1079–87.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Falk H, Herbert J, Crowley S, Ishak KG, Thomas LB, Popper H, Caldwell GG. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ Health Perspect. 1981;41:107–13.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Fujimoto M, Kiyosawa T, Murata S. Vascular endothelial growth factor in angiosarcoma. Anticancer Res. 1998;18(5B):3725–9.Google Scholar
  6. Girard C, Johnson WC, Graham JH. Cutaneous angiosarcoma. Cancer. 1970;26(4):868–83.CrossRefGoogle Scholar
  7. Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010;22(4):356–61.CrossRefPubMedGoogle Scholar
  8. Hingorani P, Eshun F, White-Collins A, Watanabe M. Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas. J Pediatr Hematol Oncol. 2012;34(7):524–7.CrossRefGoogle Scholar
  9. Hoshina D, Abe R, Yoshioka N, Saito N, Hata H, Fujita Y, Aoyagi S, Shimizu H. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment. J Dermatol Sci. 2013;70(2):116–22.CrossRefPubMedGoogle Scholar
  10. Koontz BF, Miles EF, Rubio MA. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008;30(2):262–6.CrossRefPubMedGoogle Scholar
  11. Lejeune FJ, Pujol N, Liénard D. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26(7):669–78.CrossRefPubMedGoogle Scholar
  12. Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg. 1994;168(5):451–4.CrossRefPubMedGoogle Scholar
  13. Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer. 1981;48(8):1907–21.CrossRefPubMedGoogle Scholar
  14. McConnell EM, Haslam P. Angiosarcoma in post-mastectomy lymphoedema; a report of 5 cases and a review of the literature. Br J Surg. 1959;46(198):322–32.CrossRefPubMedGoogle Scholar
  15. Miettinen M. From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol. 2006;587:99–113.CrossRefPubMedGoogle Scholar
  16. Naka N, Ohsawa M, Tomita Y. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61(3):170–6.CrossRefPubMedGoogle Scholar
  17. Ohsawa M, Naka N, Tomita Y. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer. 1995;75(12):2867–74.CrossRefPubMedGoogle Scholar
  18. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22(4):351–5.CrossRefPubMedGoogle Scholar
  19. Penel N, Lansiaux A. Adenis a Angiosarcomas and taxanes. Curr Treat Options in Oncol. 2007;8(6):428–34.CrossRefGoogle Scholar
  20. Poblet E, Gonzalez-Palacios F, Jimenez FJ. Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas. Virchows Arch. 1996;428(4-5):217–21.PubMedGoogle Scholar
  21. Rosen A, Thimon S, Ternant D, Machet MC, Paintaud G, Machet L. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol. 2010;163(1):225–722.PubMedGoogle Scholar
  22. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64–81.CrossRefPubMedGoogle Scholar
  23. Trivers GE, Cawley HL, DeBenedetti VM. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst. 1995;87(18):1400–7.CrossRefPubMedGoogle Scholar
  24. Yoo C, Kim JE, Yoon SK. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2018

Authors and Affiliations

  1. 1.The Third Xiangya Hospital of Central South UniversityChangshaChina
  2. 2.Peking University International HospitalBeijingChina

Personalised recommendations